Previous 10 | Next 10 |
home / stock / pfe / pfe articles
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (prima...
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chie...
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with pa...
How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in rec...
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepr...
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide with 391 subjects.&n...
Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial investigating its oral weight loss drug Glucagon-like peptide-1 receptor ...
Pfizer Inc. (NYSE: PFE) shares closed higher on Wednesday. The company is reportedly discontinuing its pharmaceutical sciences small molecule (PSSM...
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 06:28:00 ET Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess ...
2024-07-01 10:48:00 ET It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago....
Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board. Mr. Taraporevala served as Presid...